A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

800

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms, Castration-Resistant

Interventions

DRUG: Pasritamig
DRUG: Docetaxel
DRUG: Prednisone

Sponsor

Janssen Research & Development, LLC